• Biology, Medicine
  • Published in
    Clinical cancer research : an…
    1997

Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement.

@article{Brandes1997SalutaryCR,
  title={Salutary clinical response of prostate cancer to antiandrogen withdrawal: assessment of flutamide in an in vitro paradigm predictive of tumor growth enhancement.},
  author={LorneJ. Brandes and G M Queen and F. S. Labella},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1997},
  volume={3 8},
  pages={
          1357-61
        }
}
Salutary clinical responses to withdrawal of flutamide have been widely reported, indicating the potential of this arylalkylamine antiandrogen to stimulate the growth of prostate cancer. Flutamide is known to inhibit cytochrome P450-mediated testosterone synthesis and metabolism. Our laboratory has shown that arylalkylamine potencies in three in vitro assays of P450 binding or function correspond to a propensity of the drugs to enhance tumor growth in vivo. Accordingly, we measured inhibition… CONTINUE READING